XML 42 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1

Legal Settlements and Loss Contingencies	12 Months Ended
	Dec. 31, 2018
Legal Settlements and Loss Contingencies	NOTE 19—LEGAL SETTLEMENTS AND LOSS CONTINGENCIES: Legal settlements and loss contingencies for 2018 amounted to an income of $1,208 million, compared to a loss of $500 million and $899 million in 2017 and 2016, respectively. The 2018 income primarily consisted of the working capital adjustment with Allergan, the Rimsa settlement and reversal of the reserve recorded in the second quarter of 2017 with respect to the carvedilol patent litigation. The expenses in 2017 primarily consisted of the reserve recorded in the second quarter of 2017 following the jury trial loss in connection with the carvedilol patent litigation. As of December 31, 2018 and 2017, accrued amounts for legal settlements and loss contingencies of $562 million and $1,232 million, respectively, are recorded in accrued expenses.

X

- Definition

The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

+ Details

Name:	us-gaap_LegalMattersAndContingenciesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration